The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus‐prone mice
Open accessAbstract
Objective: Spleen tyrosine kinase (Syk) is involved in membrane‐mediated signaling in various cells, including immune cells. It is overexpressed in T cells from patients with systemic lupus erythematosus (SLE), and its inhibition has been shown to improve T cell function as well as to improve disease manifestations in (NZB × NZW)F 1 lupus‐prone mice and in patients with rheumatoid arthritis. While clinical trials examining Syk inhibition in patients with SLE are being considered, the aim of our experiments was to determine whether the therapeutic effects of Syk inhibition extend to other strains of lupus‐prone mice and whether they result in improvement in skin disease and modification of established disease. Methods: Female MRL/ lpr or BAK/BAX mice were studied. Starting either at age 4 weeks (before disease) or at age 16 weeks (after established disease) and continuing for up to 16 weeks, mice were fed chow containing the Syk inhibitor R788 or control chow. Results: We found that inhibition of Syk in MRL/ lpr and BAK/BAX mice prevented the development of skin disease and significantly reduced established skin disease. Similarly, Syk inhibition reduced the size of the spleen and lymph nodes, suppressed the development of renal disease, and suppressed established renal disease. Discontinuation of treatment resulted in extended suppression of skin disease for at least 8 weeks and suppression of renal disease for 4 weeks. Conclusion: Syk inhibition suppresses the development of lupus skin and kidney disease in lupus‐prone mice, suppresses established disease in lupus‐prone mice, and may represent a valuable treatment for patients with SLE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
LeibundGut-Landmann, S., Groß, O., Robinson, M. J., Osorio, F., Slack, E. C., Tsoni, S. V., Schweighoffer, E., Tybulewicz, V., Brown, G. D., Ruland, J., et al. (2007) · Nature Immunology · doi:10.1038/ni1460 · Cited by 1,191
Cited by
Taming lupus-a new understanding of pathogenesis is leading to clinical advances
Liu, Z., & Davidson, A. (2012) · Nature Medicine · doi:10.1038/nm.2752 · Cited by 433
Murine Models of Systemic Lupus Erythematosus
Perry, D., Sang, A., Yin, Y., Zheng, Y.-Y., & Morel, L. (2011) · BioMed Research International · doi:10.1155/2011/271694 · Cited by 378
T cells as therapeutic targets in SLE
Crispín, J. C., Kyttaris, V. C., Terhorst, C., & Tsokos, G. C. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.60 · Cited by 271
Self-citationBack to the future: oral targeted therapy for RA and other autoimmune diseases
O'Shea, J. J., Laurence, A., & McInnes, I. B. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.7 · Cited by 115
Metadata
- Authors
- Deng, G., Liu, L., Bahjat, F. R., Pine, P. R., & Tsokos, G. C.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-06-29
- Volume
- 62
- Issue
- 7
- Pages
- 2086-2092
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1530812788
- Cited by
- 172
- References
- 2
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus‐prone mice. https://app.cochat.ai/papers/10.1002/art.27452
- The paper
- Deng, G., Liu, L., Bahjat, F. R., Pine, P. R., & Tsokos, G. C. (2010). Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus‐prone mice. Arthritis & Rheumatism. https://doi.org/10.1002/art.27452
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.